X @Bloomberg - Reportify

Eli Lilly is paying $350 million upfront to collaborate with Chinese biotech Innovent in developing new treatments for cancer and immune disorders, a further vote of confidence for the innovation capabilities of the country’s drugmakers https://t.co/SViSaZ5qnn ...